Drug and Other Therapy Development Working Group

Working Group Description:

The DOTD working group is focused on helping HRA members accelerate discovery and development of drugs and other therapies in members’ areas of interest.  One current priority area is to share examples to help members better catalyze effective drug discovery, drug development, or biomarker development through collaborations or consortia among academic and industry partners.  A second current priority is to curate and share a “toolkit of toolkits” to enable member organizations to more easily identify and access existing and up-to-date resources relevant to DOTD working group goals.

In 2018, the Drug and Other Therapy Development Group is being co-chaired by:

  • James Hendrix, Director, Global Science Initiatives, Medical and Scientific Relations, Alzheimer’s Association
  • Steve Roberds, Chief Scientific Officer. Tuberous Sclerosis Alliance